Search clinical trials for: MRX34

Total 2 results

Mirna Therapeutics, Inc.
Cancer Prevention Research Institute of Texas

Terminated

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Melanoma | Lymphoma | Renal Cell Carcinoma | Multiple Myeloma | NSCLC | Primary Liver Cancer | SCLC

Korea, Republic of, United States
Mirna Therapeutics, Inc.

Withdrawn

Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions (MRX34-102)

Melanoma

3

Subscribe